Background/aim: Dermoscopy is a diagnostic tool that assists in imaging the epidermis and dermis. Although it has also started to be used to diagnose nonmelanocytic lesions recently, it has not been tested much on oral mucosal masses, such as oral mucoceles. This study aimed to investigate whether dermoscopy is a valuable tool in diagnosing oral mucoceles. Materials and methods: In this study, the clinical and dermoscopic features of 21 oral mucocele lesions of 21 patients (11 females, 10 males) aged between 6 and 38 years who were confirmed histopathologically were evaluated. Results: Of the lesions studied, 95.2% (20) were extravasation and 4.8% (1) were retention mucoceles. The nonvascular structures were determined as white areas (61.9%, 13), erythema (57.1%, 12), purplish-gray background (52.3%, 11), ulcer (30%, 8), yellowish-orange areas (23.8%, 5), crust (14.2%, 3), starburst pattern (0.95%, 2), and bleeding (0.47%, 1). Dermoscopically, 40% of extravasation mucoceles were classified as type 1 (8 patients), 25% as type 2 (5 patients), and 35% as type 3 (7 patients). Conclusion: We concluded that there are 3 types of extravasation mucoceles dermoscopically and clinically, and these types may be stages of transition between each other.

Diabetes Mellitus (DM) causes an increase in oxidative stress that leads to deterioration in auditory functions. Astaxanthine (AST) is known to have strong antioxidant effects. In this study, the aim is to investigate the effect of AST against hearing loss that is due to DM. This study is an experimental animal study. The study was designed in four groups with 8 animals (n = 8) in each group. The groups were as follows; Control Group (CNT), Diabetic Group (DM), AST applied diabetic group (DM+AST), and AST applied non-diabetic group (AST). Streptozotocin was applied in rats to induce DM. AST was administered by oral gavage. Auditory Brainstem Responses (ABR) and Distortion Product Otoacoustic Emissions (DPOAE) tests were performed on several days of the study. At the end of the study, pro-inflammatory cytokine levels were analyzed in cochlear tissue samples, and Glutathione Peroxidase (GPx), Superoxide Dismutase (SOD), Catalase (CAT) and Malondialdehyde (MDA) levels were measured. When the findings obtained in the ABR and DPOAE tests in the DM group, it was observed that there was a significant deterioration in the hearing sense. This deterioration was not observed in the DM+AST group. In the DM group, GPx, SOD and CAT levels decreased and MDA levels increased in blood and cochlear tissue. Compared to the DM group, it was noted that antioxidant enzyme levels increased and MDA levels decreased in the DM+AST group. Cochlear tissue pro-inflammatory cytokine levels, which increased with DM, were significantly decreased in the DM+AST group. Even though the effects of AST were investigated in a diabetic experimental animal model, if this molecule is proven to be effective in diabetic humans, it can be considered an adjunct therapeutic option with its antioxidant effects. The level of evidence of this article is 5. This article is an experimental animal and laboratory study.

Cisplatin (CDDP) is a widely used antineoplastic drug. However, its use is limited due to the ototoxic side effects. In this study, the effects of ethyl pyruvate (EP), known for its antioxidant and anti-inflammatory effects, against CDDP ototoxicity were investigated. Thirty-two Wistar albino rats (n:8) were used in this study. CDDP was administered i.p. as a single dose of 15 mg/kg/day in order to cause ototoxicity. EP was applied i.p. at a dose of 50 mg/kg/day for 7 days. When the Auditory Brainstem Responses (ABR) and Distortion Product Otoacoustic Emissions (DPOAE) tests carried out in the pre-treatment and post-treatment periods were examined, it was observed that the hearing functions were significantly impaired with the CDDP application, while a significant improvement was observed in the CDDP + EP group. Compared to the control group, the CDDP group had significantly higher malondialdehyde (MDA) levels and significantly lower glutathione peroxidase (GPx), superoxide dismutase (SOD) and catalase (CAT) levels. In the CDDP + EP group, there was no deterioration in MDA, SOD and CAT levels that was observed in the CDDP group. The increase in pro-inflammatory cytokine (IL-1β, IL-6 and TNF-α) levels caused by CDDP administration was observed to be significantly decreased in the CDDP + EP group. Hearing tests and biochemical results show that ethyl pyruvate is protective against cisplatin ototoxicity with its antioxidant and anti-inflammatory effects.

Background: Hearing loss is a prevalent sensory impairment with substantial psychosocial consequences. This cross-sectional study investigated the relationship between audiometric hearing loss and mood disturbances in adults aged 18–65 years who reported hearing difficulties for at least six months. Methods: Objective hearing level was assessed using the better-ear pure-tone average (PTA), and subjective hearing handicap was measured with the Hearing Handicap Inventory for Adults (HHIA). Standardized mood assessments included the Beck Depression Inventory-II (BDI-II) and the Beck Anxiety Inventory (BAI). Results: The study found that higher HHIA scores, indicating greater perceived hearing handicap, were strongly correlated with more severe depression and anxiety (ρ ≈ 0.45 and 0.38, respectively; p < 0.001). In contrast, objective PTA showed weaker associations with mood scores. Regression analyses, adjusted for age and gender, confirmed that perceived hearing handicap (HHIA) was the strongest independent predictor of both depression (standardized β ≈ 0.37, p < 0.001) and anxiety (β ≈ 0.33, p < 0.01), accounting for about 30% of the variance in mood scores. Nearly one-third of participants had clinically significant depression (BDI-II ≥ 20), which is substantially higher than community norms. The cross-sectional design and potential selection bias are limitations. Conclusions: Even mild-to-moderate hearing loss can result in significant depressive and anxious symptoms when individuals perceive themselves as handicapped. Early identification of hearing problems, routine psychosocial screening (e.g., a simple two-question survey), and integrated care are essential for improving quality of life.

Purpose: Mucormycosis is a life-threatening fungal infection, where rapid diagnosis is critical. We developed a deep learning approach using paranasal computed tomography (CT) images to test whether mucormycosis can be detected automatically, potentially aiding or expediting the diagnostic process that traditionally relies on biopsy. Methods: In this retrospective study, 794 CT images (from patients with mucormycosis, nasal polyps, or normal findings) were analyzed. Images were resized and augmented for training. Two transfer learning models (ResNet50 and ConvNeXt Small) were fine-tuned to classify images into the three categories. We employed a 70/30 train-test split (with five-fold cross-validation) and evaluated performance using accuracy, precision, recall, F1-score, and confusion matrices. Results: The ConvNeXt Small model achieved 100% accuracy on the test set (precision/recall/F1-score = 1.00 for all classes), while ResNet50 achieved 99.16% accuracy (precision ≈0.99, recall ≈0.99). Cross-validation yielded consistent results (ConvNeXt accuracy ~99% across folds), indicating no overfitting. An ablation study confirmed the benefit of transfer learning, as training ConvNeXt from scratch led to lower accuracy (~85%) Conclusions: Our findings demonstrate that deep learning models can accurately and non-invasively detect mucormycosis from CT scans, potentially flagging suspected cases for prompt treatment. These models could serve as rapid screening tools to complement standard diagnostic methods (histopathology), although we emphasize that they are adjuncts and not replacements for biopsy. Future work should validate these models on external datasets and investigate their integration into clinical workflows for earlier intervention in mucormycosis.